The present invention is directed to the prevention, reversal and medical treatment of lower urinary tract dysfunction including bladder instability and other related diseases as described below including urinary flow problems, urgency and incontinence as a result of prostate hyperplasia (BPH) and to the prevention, reversal and medical treatment of irritable bowl syndrome (IBS) with special focus on the diarrhea-predominant and mixed diarrhea-constipation type IBS, both in human beings and animals.

Elbion AG

Use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowel syndrome

The present invention provides compounds of the formula ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and n have meaning as described in the specification, methods for their preparation, and pharmaceutical compositions containing them. The compounds of formula (I) are adenosine A.sub.2B receptor agonists and, thus, may be employed for the treatment of diseases in mammals that are mediated by the A.sub.2B receptor including, but not limited to, septic shock, cystic fibrosis, impotence, diarrhea, and cardiac diseases. Cardiac diseases include hyperplasia consequent to hypertension, arteriosclerosis, and heart attack. The present invention also provides methods for the induction of pharmacological stress to facilitate coronary imaging of areas of ischemia by employing compounds of formula (I). The compounds of formula (I) may be labeled, e.g., with radioactive isotopes, and therefore are useful in kinetic binding experiments.

hyperplasia/дијареја

Use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowel syndrome

Adenosine A.sub.2B receptor agonists

Најкомплетнија база лековитог биља подржана науком